Mechanistic insights into how B7x-mediated immune evasion drives resistance to PD-1/PD-L1 blockade in bladder cancer ...
Risk of non-small cell lung cancer (NSCLC), a malignancy that develops in the tissues of the lung, increases considerably ...
Humans have been attempting to combat cancer since the time of the Ancient Egyptians, and recent decades have seen remarkable progress. However, tumor cells have developed sophisticated ways to evade ...
Survival for Head and Neck Squamous Cell Carcinoma Treated With Versus Without Neoadjuvant Systemic Therapy: A National Propensity Score–Matched Analysis Supported by National Institutes of Health; ...
Predictive value of the triglyceride-glucose index for the efficacy of immunotherapy in patients with advanced NSCLC: A retrospective study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
SEATTLE, WASHINGTON / ACCESS Newswire / May 8, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on ...
PD-1 and LAG-3 are both inhibitory immune checkpoints known for limiting T cell activity in cancer. Blocking PD-1 and LAG-3 reprograms suppressive macrophages and sustains antitumor efficacy ...
PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results